Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart IV Monotherapy in AChR Antibody–Positive Generalized Myasthenia Gravis (Master Protocol ARGX-999-2-MG-2000, ISA2)
jRCT2021260031Phase 2Recruiting
- Sponsor
- argenx
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing Empasiprubart IV monotherapy with Placebo IV (2 arms). Primary endpoints: MP primary safety endpoints and ISA2 primary safety endpoints (double-blinded treatment period). Started Aug 2026; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021260031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260031.